Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

About this update from Iovance Biotherapeutics, Inc.

[{"type":"image","alt":"Iovance Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Iovance Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CpWBAZmzJ.hidpycFVkUTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNw--/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates.","length":429,"tagName":"p"},{"type":"text","content":"To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wmx3s4fc. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.","length":279,"tagName":"p"},{"type":"text","content":"About Iovance Biotherapeutics, Inc.","length":35,"tagName":"p"},{"type":"text","content":"Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.","length":736,"tagName":"p"},{"type":"text","content":"Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered tra...

More updates from Iovance Biotherapeutics, Inc.